Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company that has pioneered the discovery of novel drugs that directly target RNA. The company's TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases that current medications cannot address. Arrakis is developing a proprietary pipeline of small molecules targeting RNA, with a focus on neurological disorders, cancer, and rare genetic diseases. Founded in 2015 by Dr. Russell Petter, Dr. Alan Walts, Henri Termeer, and Dr. Raj Parekh, the company aims to create a proprietary translational discovery platform that identifies small molecule drugs acting directly on pathogenic RNA. The company was established with seed funding from Advent Life Sciences and Henri Termeer. It brings together scientific leaders in RNA structure, chemistry, and biology, supported by an experienced management team and leading life science investors.